Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Michael J. Kelley"'
Autor:
Luca F Valle, Nicholas G Nickols, Ryan Hausler, Patrick R Alba, Tori Anglin-Foote, Cristina Perez, Kosj Yamoah, Brent S Rose, Michael J Kelley, Scott L DuVall, Isla P Garraway, Kara N Maxwell, Julie A Lynch
Publikováno v:
The oncologist, vol 28, iss 6
Oncologist
Oncologist
Black Veterans have higher a incidence of localized and metastatic prostate cancer compared to White Veterans yet are underrepresented in reports of frequencies of somatic and germline alterations. This retrospective analysis of somatic and putative
Autor:
Olivia M. Dong, Salvador Rivas, Michael Naglich, Nina R. Sperber, Catherine Chanfreau-Coffinier, Kara L. Gavin, Megan C. Roberts, Jill S Bates, Jason L. Vassy, R. Ryanne Wu, Deepak Voora, Maria Ribeiro, Michael J. Kelley, Peruvemba Sriram, Corrine I. Voils, C. William Heise, Jennifer G Chapman
Publikováno v:
Pharmacogenomics
Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distribute
Autor:
Brian Seal, Candice Yong, Trudy Buckingham, Anna Hung, Kyung Min Lee, Michael J. Kelley, Bradley J. Hintze, Yanhong Li, Shelby D. Reed, Julie Lynch, Olga V. Efimova, Pradeep J. Poonnen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
BackgroundThe Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-sm
Autor:
Meghan J. Price, Vishal Vashistha, David Winski, Michael J. Kelley, Rhonda L. Bitting, Bruce Montgomery
Publikováno v:
JCO Precis Oncol
PURPOSE Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene variants and describe real-world outcomes
Autor:
Anthony Scott, Arathi Mohan, Sarah Austin, Erika Amini, Shelby Raupp, Brittany Pannecouk, Michael J. Kelley, Goutham Narla, Nithya Ramnath
Publikováno v:
JCO Oncol Pract
PURPOSE: Increased access and utilization of tumor profiling of cancers in our veteran population uncovered a modest number of potentially pathogenic germline variants (PPGVs) that require genetics referral for follow-up evaluation and germline seque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796647242a5ef7f571dcb95d056655a4
https://europepmc.org/articles/PMC9191304/
https://europepmc.org/articles/PMC9191304/
Autor:
Michael J. Kelley, Russell Jacobitz, Craig William Heise, Susan Rozelle, Salvador Rivas, Michael Icardi, Olivia M. Dong, Jason L. Vassy, Deepak Voora, Peruvemba Sriram, Laurence Meyer, Michael Naglich, Catherine Chanfreau-Coffinier, Jennifer G Chapman, Jill S Bates, Maria Ribeiro
Publikováno v:
Pharmacogenomics. 22:137-144
In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approxima
Autor:
Joseph K. Salama, Christina D. Williams, Manisha Palta, Julian C. Hong, Michael J. Kelley, Matthew J. Boyer, Daphna Y. Spiegel
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:52-58
Background: Adjuvant chemotherapy (AC) after chemoradiation (CRT) and surgery for locoregionally advanced rectal cancer (LARC) is a standard of care in the United States. This study examined the role, optimal regimen, and duration of AC using data fr
Autor:
Shelby D. Reed, Pradeep J. Poonnen, Olivia M. Dong, David Winski, Vishal Vashistha, Michael J. Kelley, Jill Bates, Deepak Voora
Publikováno v:
Value Health
Objectives A cost-effectiveness analysis comparing comprehensive genomic profiling (CGP) of 10 oncogenes, targeted gene panel testing (TGPT) of 4 oncogenes, and no tumor profiling over the lifetime for patients with metastatic lung adenocarcinoma fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef1122630a36b25cb0422f158dc28108
https://europepmc.org/articles/PMC8976872/
https://europepmc.org/articles/PMC8976872/
Autor:
Harvey G. Moore, Julian C. Hong, Michael J. Kelley, Christina D. Williams, Daphna Y. Spiegel, Manisha Palta, Joseph K. Salama, Matthew J. Boyer
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 103:565-573
Standard therapy for locally advanced rectal cancer includes neoadjuvant chemoradiation and surgery. Complete response (CR) rates after chemoradiation can be as high as 29%, suggesting that nonoperative management (NOM) may be reasonable with appropr
Autor:
Hayden B. Bosworth, Valerie Smith, Jennifer H. Lindquist, Michael J. Kelley, Susanne Danus, Isabelle P. Sico, Dawn Provenzale, Shelley A. Jazowski, Leah L. Zullig
Publikováno v:
BMC Health Services Research
BMC Health Services Research, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Health Services Research, Vol 21, Iss 1, Pp 1-9 (2021)
Background Transportation barriers limit access to cancer care services and contribute to suboptimal clinical outcomes. Our objectives were to describe the frequency of Veterans reporting and the factors associated with transportation barriers to or